

WO 2005/072770

PCT/US2005/001139

2/26

<400> 3

Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1 5 10 15

Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu Ile His
20 25 30

Thr Ala

<210> 4

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (8)..(8)

<223> Nle

<220>

<221> MOD_RES

<222> (12)..(12)

<223> Aib

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Nle

<220>

<221> MOD_RES

<222> (23)..(23)

<223> 2-Nal

<220>

<223> see specification as filed for preferred embodiments

<400> 4

Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Xaa Lys His Leu Ser
1 5 10 15

Ser Xaa Glu Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

WO 2005/072770

PCT/US2005/001139

3/26

<210> 5
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 5
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Leu Leu Glu Lys Leu Glu Lys Leu His
20 25 30

Asn Phe

<210> 6
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 6
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Glu Lys Lys Leu Glu Lys Val His
20 25 30

Asn Phe

<210> 7
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

WO 2005/072770

PCT/US2005/001139

4/26

<220>

<223> see specification as filed for preferred embodiments

<400> 7

Ser	Val	Ser	Glu	Ile	Gln	Leu	Met	His	Asn	Leu	Gly	Lys	His	Leu	Asn
1				5				10						15.	

Ser	Met	Glu	Arg	Val	Glu	Leu	Leu	Arg	Lys	Leu	Leu	Gln	Asp	Leu	His
	20				25				30						

Asn Phe

<210> 8

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (26)..(26)

<223> Aib

<220>

<223> see specification as filed for preferred embodiments

<400> 8

Ala	Val	Ser	Glu	His	Gln	Leu	Leu	His	Asp	Lys	Gly	Lys	Ser	Ile	Gln
1				5				10					15		

Asp	Leu	Arg	Arg	Phe	Phe	Leu	His	Xaa	Leu	Ile	Ala	Glu	Ile	His	
	20				25				30						

Thr Ala

<210> 9

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

WO 2005/072770

PCT/US2005/001139

5/26

<222> (32) .. (32)
<223> Thi

<220>
<223> see specification as filed for preferred embodiments

<400> 9
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1 5 10 15

Asp Leu Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys Leu Xaa
20 25 30

Thr Ala

<210> 10
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 10
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1 5 10 15

Asp Leu Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Leu Leu His
20 25 30

Thr Ala

<210> 11
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 11
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1 5 10 15

WO 2005/072770

PCT/US2005/001139

6/26

Asp Leu Arg Arg Arg Phe Leu Leu His His Leu Leu Ala Glu Leu His
20 25 30

Thr Ala

<210> 12
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<223> see specification as filed for preferred embodiments

<400> 12
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile Gln
1 5 10 15

Asp Leu Arg Arg Arg Glu Phe Leu Glu Lys Leu Ile Glu Lys Ile His
20 25 30

Thr Ala

<210> 13
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Nal

WO 2005/072770

PCT/US2005/001139

7/26

<220>

<223> see specification as filed for preferred embodiments

<400> 13

Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1 5 10 15Ser Xaa Glu Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

<210> 14

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (8)..(8)

<223> Nle

<220>

<221> MOD_RES

<222> (18)..(19)

<223> beta-Ala

<220>

<221> MOD_RES

<222> (23)..(23)

<223> Nal

<220>

<223> see specification as filed for preferred embodiments

<400> 14

Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1 5 10 15Ser Xaa Xaa Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

WO 2005/072770

PCT/US2005/001139

8/26

<210> 15
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 15
Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

<210> 16
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES

WO 2005/072770

PCT/US2005/001139

9/26

<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 16
Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

<210> 17
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

WO 2005/072770

PCT/US2005/001139

10/26

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (23)..(23)
<223> Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 17
Ala Val Ser Glu Ile Gln Phe Xaa His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

<210> 18
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (16)..(16)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<223> see specification as filed for preferred embodiments

<400> 18
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Xaa
1 5 10 15

Ser Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

WO 2005/072770

PCT/US2005/001139

11/26

Asn Phe

<210> 19
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (20)..(20)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 19
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Glu Xaa Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 20
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES

WO 2005/072770

PCT/US2005/001139

12/26

<222> (18) .. (18)
<223> Nle

<220>
<223> see specification as filed for preferred embodiments

<400> 20
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 21
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18) .. (18)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 21
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 22
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

WO 2005/072770

PCT/US2005/001139

13/26

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 22
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 23
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<223> see specification as filed for preferred embodiments

<400> 23
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

WO 2005/072770

PCT/US2005/001139

14/26

Asn Phe

<210> 24
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<223> see specification as filed for preferred embodiments

<400> 24
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Ser Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 25
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

WO 2005/072770

PCT/US2005/001139

15/26

<400> 25

Ala	Val	Ser	Glu	Ile	Gln	Phe	Met	His	Asn	Leu	Gly	Lys	His	Leu	Ser
1				5				10						15	

Ser	Xaa	Xaa	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
				20				25						30	

Asn Phe

<210> 26

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (17)..(17)

<223> beta-Ala

<220>

<221> MOD_RES

<222> (18)..(18)

<223> beta-Ala

<220>

<223> see specification as filed for preferred embodiments

<400> 26

Ala	Val	Ser	Glu	Ile	Gln	Phe	Met	His	Asn	Leu	Gly	Lys	His	Leu	Ser
1				5				10						15	

Xaa	Xaa	Glu	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
				20				25						30	

Asn Phe

<210> 27

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

WO 2005/072770

PCT/US2005/001139

16/26

<220>

<221> MOD_RES

<222> (18)..(19)

<223> beta-Ala

<220>

<223> see specification as filed for preferred embodiments

<400> 27

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15Ser Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 28

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (17)..(17)

<223> beta-Ala

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Nle

<220>

<221> MOD_RES

<222> (19)..(19)

<223> beta-Ala

<220>

<223> see specification as filed for preferred embodiments

<400> 28

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

WO 2005/072770

PCT/US2005/001139

17/26

Asn Phe

<210> 29
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<223> see specification as filed for preferred embodiments

<400> 29
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 30
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

WO 2005/072770

PCT/US2005/001139

18/26

<220>

<223> see specification as filed for preferred embodiments

<400> 30

Ala	Val	Ser	Glu	Ile	Gln	Phe	Met	His	Asn	Leu	Gly	Lys	His	Leu	Ser
1				5				10					15		

Ser	Xaa	Xaa	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
				20			25					30			

Asn Phe

<210> 31

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (18)..(18)

<223> beta-Ala

<220>

<221> MOD_RES

<222> (19)..(19)

<223> beta-hGlu

<220>

<223> see specification as filed for preferred embodiments

<400> 31

Ala	Val	Ser	Glu	Ile	Gln	Phe	Met	His	Asn	Leu	Gly	Lys	His	Leu	Ser
1					5			10				15			

Ser	Xaa	Xaa	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
				20			25					30			

Asn Phe

<210> 32

<211> 34

<212> PRT

<213> Artificial Sequence

WO 2005/072770

PCT/US2005/001139

19/26

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

<400> 32
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 33
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES

WO 2005/072770

PCT/US2005/001139

20/26

<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 33
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 34
<211> 35
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 34
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val
20 25 30

His Asn Phe
35

WO 2005/072770

PCT/US2005/001139

21/26

<210> 35
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-Ala

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-Ala

<220>
<223> see specification as filed for preferred embodiments

<400> 35
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 36
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(18)
<223> beta-Ala

WO 2005/072770

PCT/US2005/001139

22/26

<220>

<221> MOD_RES

<222> (19)..(19)

<223> beta-hGlu

<220>

<223> see specification as filed for preferred embodiments

<400> 36

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 37

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (17)..(17)

<223> beta-Ala

<220>

<221> MOD_RES

<222> (18)..(18)

<223> beta-hLeu

<220>

<221> MOD_RES

<222> (19)..(19)

<223> beta-Ala

<220>

<223> see specification as filed for preferred embodiments

<400> 37

Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

WO 2005/072770

PCT/US2005/001139

23/26

Asn Phe

<210> 38
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<223> see specification as filed for preferred embodiments

<400> 38
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 39
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

WO 2005/072770

PCT/US2005/001139

24/26

<220>

<223> see specification as filed for preferred embodiments

<400> 39

Ala	Val	Ser	Glu	Ile	Gln	Phe	Met	His	Asn	Leu	Gly	Lys	His	Leu	Ser
1				5				10						15	

Ser	Xaa	Xaa	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
	20				25								30		

Asn Phe

<210> 40

<211> 34

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<220>

<221> MOD_RES

<222> (17)..(17)

<223> beta-hSer

<220>

<221> MOD_RES

<222> (18)..(18)

<223> Nle

<220>

<221> MOD_RES

<222> (19)..(19)

<223> beta-hGlu

<220>

<223> see specification as filed for preferred embodiments

<400> 40

Ala	Val	Ser	Glu	Ile	Gln	Phe	Met	His	Asn	Leu	Gly	Lys	His	Leu	Ser
1					5			10					15		

Xaa	Xaa	Xaa	Arg	Val	Glu	Trp	Leu	Arg	Lys	Lys	Leu	Gln	Asp	Val	His
	20				25							30			

Asn Phe

WO 2005/072770

PCT/US2005/001139

25/26

<210> 41
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (17)..(17)
<223> beta-hSer

<220>
<221> MOD_RES
<222> (18)..(18)
<223> beta-hLeu

<220>
<221> MOD_RES
<222> (19)..(19)
<223> beta-hGlu

<220>
<223> see specification as filed for preferred embodiments

<400> 41
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu Ser
1 5 10 15

Xaa Xaa Xaa Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe

<210> 42
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Nle

<220>
<221> MOD_RES

WO 2005/072770

PCT/US2005/001139

26/26

<222> (12)..(12)
<223> Aib

<220>
<221> MOD_RES
<222> (18)..(18)
<223> Nle

<220>
<221> MOD_RES
<222> (23)..(23)
<223> 2-Nal

<220>
<223> see specification as filed for preferred embodiments

<400> 42
Ser Val Ser Glu Ile Gln Leu Xaa His Asn Leu Xaa Lys His Leu Asn
1 5 10 15

Ser Xaa Glu Arg Val Glu Xaa Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Tyr

<210> 43
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic peptide

<220>
<221> MOD_RES
<222> (12)..(12)
<223> Aib

<220>
<223> see specification as filed for preferred embodiments

<400> 43
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Xaa Lys His Leu Asn
1 5 10 15

Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30

Asn Phe